Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice.

ZJ Franklin, LM McShane, Finbarr O'Harte, Nigel Irwin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Modification to the structure of glucagon has provided a number of glucagon receptor antagonists with possible therapeutic application for diabetes. These novel peptide analogs include desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon. This study has evaluated the metabolic benefits of once daily administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon in high fat (45%) fed mice for 15 days. Administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon had no significant effect on body weight, food intake or circulating glucose concentrations during the treatment period. However, both peptides significantly (P
LanguageEnglish
Pages95-101
JournalPeptides
Volume60
DOIs
Publication statusPublished - 18 Aug 2014

Fingerprint

Glucagon Receptors
Ablation
Glucagon
Fats
Glucose
Peptides
Medical problems
Eating
Body Weight

Cite this

@article{0987d86389954691b421ecbe10f55ef7,
title = "Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice.",
abstract = "Modification to the structure of glucagon has provided a number of glucagon receptor antagonists with possible therapeutic application for diabetes. These novel peptide analogs include desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon. This study has evaluated the metabolic benefits of once daily administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon in high fat (45{\%}) fed mice for 15 days. Administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon had no significant effect on body weight, food intake or circulating glucose concentrations during the treatment period. However, both peptides significantly (P",
author = "ZJ Franklin and LM McShane and Finbarr O'Harte and Nigel Irwin",
year = "2014",
month = "8",
day = "18",
doi = "10.1016/j.peptides.2014.08.002",
language = "English",
volume = "60",
pages = "95--101",

}

Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice. / Franklin, ZJ; McShane, LM; O'Harte, Finbarr; Irwin, Nigel.

Vol. 60, 18.08.2014, p. 95-101.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice.

AU - Franklin, ZJ

AU - McShane, LM

AU - O'Harte, Finbarr

AU - Irwin, Nigel

PY - 2014/8/18

Y1 - 2014/8/18

N2 - Modification to the structure of glucagon has provided a number of glucagon receptor antagonists with possible therapeutic application for diabetes. These novel peptide analogs include desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon. This study has evaluated the metabolic benefits of once daily administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon in high fat (45%) fed mice for 15 days. Administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon had no significant effect on body weight, food intake or circulating glucose concentrations during the treatment period. However, both peptides significantly (P

AB - Modification to the structure of glucagon has provided a number of glucagon receptor antagonists with possible therapeutic application for diabetes. These novel peptide analogs include desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon. This study has evaluated the metabolic benefits of once daily administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon in high fat (45%) fed mice for 15 days. Administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon had no significant effect on body weight, food intake or circulating glucose concentrations during the treatment period. However, both peptides significantly (P

U2 - 10.1016/j.peptides.2014.08.002

DO - 10.1016/j.peptides.2014.08.002

M3 - Article

VL - 60

SP - 95

EP - 101

ER -